➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
Express Scripts
Baxter
Mallinckrodt
Harvard Business School
Boehringer Ingelheim

Last Updated: March 4, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR GS-0976

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Clinical Trials for GS-0976

Trial ID Title Status Sponsor Phase Summary
NCT02781584 Safety, Tolerability, and Efficacy of GS-4997, GS-0976, and GS-9674 in Adults With Hepatic Steatosis and Elevated Liver Stiffness Recruiting Gilead Sciences Phase 2 The primary objective of this study is to evaluate the safety and tolerability of GS-4997, GS-0976, and GS-9674 in adults with hepatic steatosis and elevated liver stiffness.
NCT02856555 GS-0976 in Adults With Nonalcoholic Steatohepatitis Recruiting Gilead Sciences Phase 2 The primary objective of this study is to evaluate the safety and tolerability of GS-0976 in adults with nonalcoholic steatohepatitis (NASH).
NCT02876796 Study to Evaluate the Pharmacodynamic Effects of a Single Oral Dose of GS-0976 (NDI-010976) in Healthy Adult Subjects Completed Nimbus Apollo Phase 1 The primary objective of this study is to assess the pharmacodynamic (PD) effects of GS-0976 (NDI-010976) on fractional de novo lipogenesis (DNL) following a single oral dose administration in overweight and/or obese, but otherwise healthy, male adults.
NCT02876796 Study to Evaluate the Pharmacodynamic Effects of a Single Oral Dose of GS-0976 (NDI-010976) in Healthy Adult Subjects Completed Gilead Sciences Phase 1 The primary objective of this study is to assess the pharmacodynamic (PD) effects of GS-0976 (NDI-010976) on fractional de novo lipogenesis (DNL) following a single oral dose administration in overweight and/or obese, but otherwise healthy, male adults.
>Trial ID >Title >Status >Phase >Summary

Clinical Trial Conditions for GS-0976

Condition Name

Condition Name for
Intervention Trials
Nonalcoholic Steatohepatitis (NASH) 2
Nonalcoholic Steatohepatitis 2
PD Effects of GS-0976 (NDI-010976) on Fractional DNL 1
Non-alcoholic Fatty Liver Disease (NAFLD) 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for
Intervention Trials
Fatty Liver 5
Non-alcoholic Fatty Liver Disease 5
Liver Diseases 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for GS-0976

Trials by Country

Trials by Country for
Location Trials
United States 56
Australia 5
Hong Kong 1
Canada 1
Puerto Rico 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for
Location Trials
Texas 4
Minnesota 3
Florida 3
New York 2
Georgia 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for GS-0976

Clinical Trial Phase

Clinical Trial Phase for
Clinical Trial Phase Trials
Phase 2 4
Phase 1 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for
Clinical Trial Phase Trials
Recruiting 4
Completed 1
Not yet recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for GS-0976

Sponsor Name

Sponsor Name for
Sponsor Trials
Gilead Sciences 6
Novo Nordisk A/S 1
Nimbus Apollo 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for
Sponsor Trials
Industry 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Express Scripts
Moodys
Harvard Business School
Mallinckrodt
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.